Interestingly, 37% of patients with AML who failed Gilteritinib therapy exhibited RAS/MAPK mutations as well as the emergence of additional new mutations (including BRAF, CBL, KRAS, PTPN11, RUNX1, WT1, and CEBPA), which were undetected prior to Gilteritinib treatment (2). The gene discussed is WT1; the disease is acute myeloid leukemia.